Immune privilege and angiogenic privilege of the cornea

Chemical Immunology and Allergy

Volumn 92, Issue , 2007, Pages 50-57

  Cursiefen, Claus ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; ANGIOGENESIS INHIBITOR; CLODRONIC ACID; FAS ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; THROMBOSPONDIN; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 3; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANGIOGENESIS; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CORNEA DISEASE; CORNEA TRANSPLANTATION; DISEASE ASSOCIATION; DISEASE COURSE; GRAFT REJECTION; GRAFT SURVIVAL; HERPES SIMPLEX KERATITIS; HISTOCOMPATIBILITY; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATORY CELL; KERATITIS; KERATOPLASTY; LYMPHANGIOGENESIS; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SCAR FORMATION; TISSUE INJURY; TREATMENT OUTCOME; VISION; ANIMAL; CORNEA; IMMUNOLOGY; REVIEW; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CORNEA; CORNEAL TRANSPLANTATION; HUMANS; LYMPHANGIOGENESIS; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 33947509344     PISSN: 16602242     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000099253     Document Type: Article

References (30)

1. Streilein JW: OculaT immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 2003;3:879-889.
2. Streilein JW: OculaT immune privilege: the eye takes a dim but practical view of immunity and inflammation. J Leukoc Biol 2003;74:179-185.
3. Cursiefen C, Kruse FE: New aspects of corneal angiogenesis; in Reinhard T, Larkin F (eds): Cornea and External Eye; in Krieglstein GK, Weinreb RN (ser eds): Essentials in Ophthalmology. New York, Springer, 2006, pp 83-99.
4. Chang JH, Gabison EE, Kato T, Azar DT: Corneal neovascularization. Curr Opin Ophthalmol 2001;12:242-249.
5. Streilein JW, Yamada J, Dana MR, Ksander BR: Anterior chamber-associated immune deviation, ocular immune privilege, and orthotopic corneal allografts. Transplant Proc 1999;31:1472-1475.
6. Niederkorn JY: The immune privilege of corneal allografts. Transplantation 1999;67:503-508.
7. Streilein JW: New thoughts on the immunology of corneal transplantation. Eye 2003;17:943-948.
8. Cursiefen C, Chen L, Dana MR, Streilein JW: Corneal lymphangiogenesis: evidence, mechanisms and implications for transplant immunology. Cornea 2003;22:273-281.
9. Cursiefen C, Maruyama K, Liu Y, Chen L, Jackson D, Wiegand S, Dana MR, Streilein JW: Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 2004;45: 2666-2673.
10. Cursiefen C, Chen L, Borges L, Jackson D, Cao J, Radziejewski C, D'Amore PA, Dana MR, Wiegand SJ, Streilein JW: VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004;113:1040-1050.
11. Hori J, Jouyce N, Streilein JW: Epithelium-deficient corneal allografts display immune privilege beneath the kidney capsule. Invest Ophthalmol Vis Sci 2000;41:443-452.
12. Cursiefen C, Masli S, Ng TF, Dana MR, Bornstein P, Lawler J, Streilein JW: Roles of thrombospondin 1 and 2 in regulating spontaneous and induced angiogenesis in the cornea and iris. Invest Ophthalmol Vis Sci 2004;45:1117-1124.
13. Dana MR, Streilein JW: Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci 1996;37:2485-2494.
14. Chen L, Hamrah P, Cursiefen C, Jackson D, Streilein JW, Dana MR: Vascular endothelial growth factor receptor-3 (VEGFR-3) mediates dendritic cell migration to lymph nodes and induction of immunity to corneal transplants. Nat Med 2004;10:813-815.
15. Cao J, Renard R, Song H, Ioffe E, Mosher V, Rudge JS, Koehler-Stec EM, Yancopoulos GD, Wiegand SJ: Inhibition of IL-1 blocks corneal inflammation and neovascularization. Invest Ophthalmol Vis Sci 2003;44:E823.
16. Maruyama K, Li M, Cursiefen C, Jackson DG, Keino H, Tomita M, Van Rooijen N, Takenaka H, D'Amore PA, Stein-Streilein J, Losordo DW, Streilein JW: Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest 2005;115: 2363-2372.
17. Diaz-Araya CM, Madigan MC, Provis JM, Penfold PL: Immunohistochemical and topographic studies of dendritic cells and macrophages in human fetal cornea. Invest Ophthalmol Vis Sci 1995;36:644-656.
18. Hamrah P, Zhang Q, Liu Y, Dana MR: Novel characterization of MHC class II-negative population of resident corneal Langerhans cell-type dendritic cells. Invest Ophthalmol Vis Sci 2002;43: 639-646.
19. Brisette-Storkus C, Reynolds S, Lepisto A, Hendricks RL: Identification of a novel macrophage population in the normal mouse corneal stroma. Invest Ophthalmol Vis Sci 2002;43:2264-2271.
20. Lai CM, Brankov M, Zaknich T, Lai YK, Shen WY, Constable IJ, Kovesdi I, Rakoczy PE: Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum Gene Ther 2001;12:1299-1310.
21. Fannon M, Forsten-Willimas K, Dowd CJ, Freedmann DA, Folkman J, Nugent MA: Binding inhibition of angiogenic factors by heparan sulfate proteoglycans in aqueous humor: Potential mechanism for maintenance of an avascular environment. FASEB J 2003;17:902-904.
22. Sano Y, Ksander BR, Streilein JW: Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction. Invest Ophthalmol Vis Sci 1995;36: 2176-2185.
23. Maguire MG, Stark WJ, Gottsch JD, Stulting RD, Sugar A, Fink NE, Schwartz A; Collaborative Corneal Transplantation Studies Research Group: Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Ophthalmology 1994;101:1536-1547.
24. Cursiefen C, Wenkel H, Martus P, Langenbucher A, Nguyen N, Seitz B, Küchle M, Naumann GOH: Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty. Graefes Arch Clin Exp Ophthalmol 2001;239:514-521.
25. Bachmann B, Lütjen-Drecoll E, Wiegand SJ, Streilein JW, Kruse FE, Cursiefen C: Inhibition of angiogenesis and lymphangiogenesis after high-risk keratoplasty by neutralizing VEGF-A improves corneal graft survival. Invest Ophthalmol Vis Sci 2005;46:E4743.
26. Slegers TP, van der Gaag R, van Rooijen N, van Rij G, Streilein JW: Effect of local macrophage depletion on cellular immunity and tolerance evoked by corneal allografts. Curr Eye Res 2003;26:73-79.
27. Cursiefen C, Schlötzer-Schrehardt U, Küchle M, Sorokin L, Breitender-Geleff S, Alitalo K, Jackson D: Lymphatic vessels in vascularized human corneas: Immunohistochemical investigation using LYVE-1 and podoplanin. Invest Ophthalmol Vis Sci 2002;43:2127-2135.
28. Cursiefen C, Ikeda S, Nishina PM, Smith RS, Ikeda A, Jackson D, Mo JS, Chen L, Dana RM, Pytowski B, Kruse FE, Streilein JW: Spontaneous corneal hem- and lymphangiogenesis in mice with destrin-mutation depend on VEGFR3 signaling. Am J Pathol 2005;166:1367-1377.
29. Zheng M, Schwarz MA, Lee S, Kumaraguru U, Rouse BT: Control of stromal keratitis by inhibition of neovascularization. Am J Pathol 2001;159:1021-1029.
30. Cursiefen C, Chen L, Saint-Geniez M, Hamrah P, Jin Y, Rashid S, Pytowski B, Persaud K, Wu Y, Streilein JW, Dana R: Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci 2006;103:11405-11410.